Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors) |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 2 | CN | 01 Oct 2024 | |
KRAS G12D mutation Solid Tumors | Phase 2 | CN | 05 Jul 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Jul 2024 |
NCT05533463 (ESMO2023) Manual | Phase 1 | KRAS G12D mutation Solid Tumors KRAS G12D | 18 | (advanced solid tumors harboring KRAS G12D mutation) | (plmgvmfzym) = fevwoswwqb aikvaqqkhb (gcjzabmrwj ) View more | Positive | 22 Oct 2023 |